Abstract:Background Although metformin, a first-line drug for treating diabetes, may play an important role in inhibition of epithelial ovarian cancer cell growth and cancer stem cells (CSCs), metformin at low dose showed less effect on the proliferation of ovarian cancer cells. In this study, we evaluated the effect of metformin at low dose on ovarian CSCs in order to understand the molecular mechanisms underlying. Methods The inhibitory effects of metformin at los dose on proliferation and population of ovarian cancer cells including SKOV3 and A2780 were assessed by cell proliferation assay and flow cytometry. Quantitative real-time PCR assay on expression of Bcl-2, Survivin and Bax was performed to determine the effect of metformin at low dose on epithelial-mesenchymal transition (EMT) of cancer cells and CSCs. Tumor sphere formation assay was also performed to evaluate the effect of metformin on spheres forming ability of CSCs. The therapeutic efficacy and the anti-CSC effects of metformin at low dose were investigated by using both SKOV3 cells and primary tumor xenografts. In addition, the CSC frequency and EMT in tumor xenograft models were also assessed by flow cytometry and quantitative real-time PCR. Results Metformin at low dose did not affect the proliferation of ovarian cancer cells. However, it inhibited population of CD44 + CD117 + selectively, neither CD133 + nor ALDH + cells. It suppressed expression of snail2, twist and vimentin significantly in cancer cells and CD44 + CD117 + CSCs in vitro . Low dose of metformin reduced survivin expression in CSCs. Low concentrations of metformin inhibited the secondary and the tertiary tumor sphere formation, decreased SKOV3 and primary ovarian tumor xenograft growth, enhanced the anticancer effect of cisplatin, and lowered the proportion of CD44 + CD117 + CSCs in the xenograft tissue. Metformin was also associated with a reduction of snail2, twist, and vimentin in CD44 + CD117 + ovarian CSCs in vivo . Conclusions Our results implicate that metformin at low dose inhibits selectively CD44 + CD117 + ovarian CSCs through inhibition of EMT and potentiates the effect of cisplatin.

Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway

Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Figure S1 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Figure S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells.

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer

[Metformin inhibits proliferation and promotes apoptosis of HER-2 positive breast cancer cells possibly through the Hippo-YAP pathway]

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production

Metformin exerts anti-tumor effects via Sonic hedgehog signaling pathway by targeting AMPK in HepG2 cells.

Metformin inhibits migration and epithelial-to-mesenchymal transition in non-small cell lung cancer cells through AMPK-mediated GDF15 induction

Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Metformin Use on Incidence and Oncologic Outcomes of Bladder Cancer Patients With T2DM: An Updated Meta-Analysis

Metformin suppresses gastric tumorigenesis by regulating chemokine CXCR 4

Metformin Suppresses the Esophageal Carcinogenesis in Rats Treated with NMBzA Through Inhibiting AMPK/mTOR Signaling Pathway

Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells

Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44 + CD117 + ovarian cancer stem cells

Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling

Metformin and Cancer: an Existing Drug for Cancer Prevention and Therapy (Review)